Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma - 14/02/14
Abstract |
Background |
Quantitation of circulating tumor cells (CTCs) has utility in managing breast, colon, and prostate carcinomas.
Objective |
We sought to determine whether a commercially available CTC assay provides prognostic information in Merkel cell carcinoma (MCC), insight into treatment responses, or both.
Methods |
We analyzed CTCs in 52 specimens from 34 patients with MCC.
Results |
The presence of CTCs correlated with extent of disease at blood draw (P = .004). Among 15 patients with regional nodal disease, CTC-negative patients had 80% disease-specific survival at 2 years after the test, versus 29% for CTC-positive patients (P = .015). Among the entire cohort, those without CTCs had 72% MCC-specific survival whereas CTC-positive patients had 25% survival (n = 34, median follow-up 19 months, P = .0003). Fifty seven percent of patients with MCC had a cytokeratin “dot” visible in 20% or more of CTCs, a feature that was absent among CTCs from other carcinomas (0 of 13 cases).
Limitations |
CTC assay was performed at variable times after diagnosis and heterogeneity in extent of disease affects interpretability of the data.
Conclusion |
CTC detection in MCC is feasible and appears to add prognostic information, particularly in patients with regional nodal disease. It may also assist clinical management in certain situations, including differentiating metastatic MCC cells from those of other carcinomas.
Le texte complet de cet article est disponible en PDF.Key words : biomarker, circulating tumor cells, dot-like cytokeratin, Merkel cell carcinoma, neuroendocrine carcinoma of the skin, prognosis
Plan
| Supported by American Cancer Society RSG-08-115-01-CCE, National Institutes of Health (NIH) K24-CA139052, NIH R01-CA162522-01, the David and Rosalind Bloom Endowment for Merkel Cell Carcinoma Research, the Michael Piepkorn Endowment Fund, and the University of Washington Merkel Cell Carcinoma Patient Gift Fund. |
|
| Disclosure: Dr Sabath receives salary support and research funding from RareCyte Corp, a start-up company that is developing a competing technology for circulating tumor cell detection. Drs Blom, Bhatia, Iyer, Nagase, Paulson, and Nghiem, Ms Pietromonaco, and Ms Koehler have no conflicts of interest to declare. |
Vol 70 - N° 3
P. 449-455 - mars 2014 Retour au numéro
Article précédent
- Incidence of lentigo maligna in Olmsted County, Minnesota, 1970 to 2007
- Sultan A. Mirzoyev, Richelle M. Knudson, Kurtis B. Reed, Jennifer L. Hou, Christine M. Lohse, Marcus L. Frohm, Jerry D. Brewer, Clark C. Otley, Randall K. Roenigk
- Basal cell carcinoma and squamous cell carcinoma growth rates and determinants of size in community patients
- Anne Kricker, Bruce Armstrong, Vibeke Hansen, Alan Watson, Gurpreet Singh-Khaira, Christophe Lecathelinais, Chris Goumas, Afaf Girgis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?